Your Patients Need Saizen — Here's How to Help Them Get It

When you prescribe Saizen (Somatropin) for growth hormone deficiency, the clinical decision is just the beginning. For many patients, the real challenge starts at the pharmacy counter — or more accurately, at the specialty pharmacy phone line.

As a provider, you're in a unique position to smooth this process. Your office's familiarity with specialty pharmacy workflows, prior authorization requirements, and alternative options can mean the difference between a patient starting therapy promptly or waiting weeks in limbo.

This guide covers the practical steps your practice can take to help patients access Saizen — and what to do when it's truly unavailable.

Current Availability: What You Need to Know

Saizen is manufactured by EMD Serono and is distributed exclusively through specialty pharmacy channels. Key facts for 2026:

• No formal FDA shortage — Saizen is not listed on the FDA drug shortage database
• Specialty pharmacy only — Retail pharmacies do not stock Saizen; dispensing requires specialty pharmacy infrastructure
• Formulary variation — Coverage and preferred status vary significantly across payers; some plans exclude Saizen entirely
• Regional gaps — Availability through specialty pharmacies can vary by region, with some areas experiencing longer delivery timelines

Why Patients Can't Find Saizen

Understanding the root causes helps you anticipate and address problems before they delay treatment:

Specialty Distribution Model

Unlike oral medications available at any retail pharmacy, Saizen requires cold-chain storage and is dispensed only through specialty pharmacies equipped for biologic medications. Patients accustomed to walking into their local pharmacy and picking up a prescription will find this process unfamiliar and frustrating.

Prior Authorization Delays

Growth hormone therapy requires prior authorization from virtually every payer. The documentation burden is significant, and incomplete submissions are the most common cause of delays. A prior auth that should take 3-5 business days can stretch to 2-3 weeks if additional information is requested.

Formulary Exclusions

Several major payers have moved Saizen to non-preferred tiers or excluded it from their formularies in favor of Norditropin, Omnitrope, or other competing brands. When a patient presents with a Saizen prescription but their plan doesn't cover it, the resulting back-and-forth can add significant delays.

Cost Barriers

Even with insurance, growth hormone therapy often comes with substantial copays. Without insurance, Saizen costs $737-$1,500 per vial, with monthly costs reaching $3,000+. Patients may abandon prescriptions they can't afford, even if the medication is technically available.

What Providers Can Do: 5 Practical Steps

Step 1: Verify Formulary Status Before Prescribing

Before writing the prescription, check your patient's formulary. This simple step can prevent weeks of delays:

• Use the patient's insurance portal or call the pharmacy benefit manager (PBM)
• Confirm whether Saizen is covered, preferred, non-preferred, or excluded
• If Saizen is not covered, identify the plan's preferred somatropin brand
• Document the medical necessity for Saizen specifically if you're requesting a non-preferred brand

Step 2: Submit a Complete Prior Authorization

Incomplete prior authorization requests are the number one cause of preventable delays. Build a standardized checklist for your GH prior auth submissions:

• Confirmed GHD diagnosis with provocative testing results (include peak GH levels)
• Baseline IGF-1 level
• For pediatric patients: height percentile, growth velocity, bone age assessment
• For adult patients: etiology of GHD (pituitary disease, surgery, radiation, childhood-onset retesting)
• Previous therapies tried (if step therapy applies)
• Clinical rationale for brand-specific request (if applicable)

Pre-populating this documentation in your EHR templates can save significant staff time.

Step 3: Establish Specialty Pharmacy Relationships

Maintain active relationships with 2-3 specialty pharmacies that dispense growth hormones. Benefits include:

• Faster processing when your office is a known referral source
• Direct lines to pharmacists who understand GH therapy
• Backup options if one pharmacy has supply constraints
• Coordination on patient education and injection training

When possible, send prescriptions to the specialty pharmacy proactively rather than waiting for the patient to initiate the process.

Step 4: Leverage Medfinder for Real-Time Availability

Medfinder for Providers helps your practice identify pharmacies with Saizen in stock. Integrate this tool into your care coordination workflow:

• Check availability before directing patients to a specific pharmacy
• Share medfinder.com/providers with patients for self-service checking
• Use availability data to inform your prescribing decisions (e.g., if Saizen is unavailable but Norditropin is readily available)

Step 5: Connect Patients With Financial Assistance

Cost is a significant barrier to adherence. Proactively connecting patients with savings resources improves fill rates:

• EMD Serono Patient Assistance Program: Free medication for qualifying uninsured/underinsured patients
• Prescription Hope: $70/month for Saizen through their patient assistance service
• GoodRx coupons: Prices as low as ~$287 at select pharmacies
• NeedyMeds/RxAssist: Databases of additional assistance programs

Your staff can include these resources in patient intake packets or post-visit summaries. For a patient-facing guide, share: How to save money on Saizen.

Alternative Somatropin Products

When Saizen is unavailable or not covered, these alternatives offer equivalent therapeutic outcomes:

• Norditropin FlexPro (Novo Nordisk) — Pre-filled pen, frequently preferred by payers, no reconstitution
• Genotropin (Pfizer) — GoQuick pen and Miniquick devices, broad indication coverage
• Omnitrope (Sandoz) — Biosimilar, typically lowest cost, good formulary placement
• Humatrope (Eli Lilly) — Vials and pen cartridges, long-established track record
• Sogroya (Novo Nordisk) — Once-weekly somapacitan for adult GHD
• Skytrofa (Ascendis Pharma) — Once-weekly lonapegsomatropin for pediatric GHD

Dose conversion between daily somatropin brands is 1:1 on a mg basis. Monitor IGF-1 levels 4-6 weeks post-switch. For weekly formulations, consult product-specific dosing guidelines.

See also: Alternatives to Saizen.

Workflow Tips for Your Practice

• Build GH-specific prior auth templates in your EHR to reduce documentation time
• Assign a dedicated staff member to manage specialty pharmacy communications and prior auth follow-up
• Set refill reminders for patients on growth hormone therapy — start the process 10+ days before supply runs out
• Track formulary changes at the start of each plan year (January) to anticipate access disruptions
• Bookmark Medfinder for Providers for quick availability checks

Final Thoughts

Getting Saizen into your patients' hands requires more than writing a prescription. It takes formulary awareness, complete documentation, specialty pharmacy coordination, and proactive cost support. The good news is that these are all manageable with the right systems in place.

For a patient-facing overview of the current availability situation, share: Saizen shortage update: What patients need to know in 2026.

Need to help patients find the right prescriber? Direct them to: How to find a doctor who can prescribe Saizen near you.